1. Home
  2. FOXX vs SCYX Comparison

FOXX vs SCYX Comparison

Compare FOXX & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foxx Development Holdings Inc.

FOXX

Foxx Development Holdings Inc.

N/A

Current Price

$4.00

Market Cap

34.0M

Sector

N/A

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$0.92

Market Cap

32.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FOXX
SCYX
Founded
2017
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.0M
32.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
FOXX
SCYX
Price
$4.00
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
8.5K
350.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
$90.24
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.57
52 Week High
$8.70
$1.29

Technical Indicators

Market Signals
Indicator
FOXX
SCYX
Relative Strength Index (RSI) 39.60 67.01
Support Level $3.80 $0.69
Resistance Level $4.80 $1.02
Average True Range (ATR) 0.40 0.05
MACD -0.12 0.01
Stochastic Oscillator 5.03 82.93

Price Performance

Historical Comparison
FOXX
SCYX

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: